Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma

Documenti analoghi

• Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
  di: Tseng, Jeng-Sen, et al.
  Pubblicazione: (2014)
• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  di: Tseng, Jeng-Sen, et al.
  Pubblicazione: (2016)
• Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
  di: Su, Kang-Yi, et al.
  Pubblicazione: (2018)
• Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
  di: Hsu, Kuo-Hsuan, et al.
  Pubblicazione: (2016)
• EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
  di: Chen, Hsuan-Yu, et al.
  Pubblicazione: (2016)